title: Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks.
abstract: OBJECTIVE
  To evaluate the effects of intravitreal bevacizumab injections in the treatment of nonsubfoveal choroidal neovascularization (CNV) associated with angioid streaks.
  
  
  METHODS
  Nonrandomized, interventional, prospective case series.
  
  
  METHODS
  Fifteen patients (15 eyes) affected by juxtafoveal or extrafoveal CNV secondary to angioid streaks were enrolled in the study. All patients underwent a complete ophthalmologic examination, including best-corrected visual acuity (BCVA) measurement on Early Treatment Diabetic Retinopathy Study (ETDRS) chart, optical coherence tomography (OCT), and fluorescein angiography (FA). The protocol treatment included a first injection, followed by repeated injections over a 12-month follow-up period on the basis of the detection of new hemorrhage on biomicroscopic examination, any type of fluid on OCT, or presence of leakage on FA.
  
  
  METHODS
  Mean changes in BCVA and proportion of eyes gaining at least 10 letters (2 ETDRS lines) at the end of the follow-up.
  
  
  RESULTS
  Mean changes of central macular thickness (CMT) and extension to the fovea.
  
  
  RESULTS
  Mean BCVA did not change throughout the follow-up period, being 0.2 ± 0.2 logMAR at baseline and 0.2 ± 0.3 logMAR at the 12-month examination. A functional improvement of at least 2 ETDRS lines was achieved by 5 eyes (33%), with 3 eyes (20%) gaining 3 lines. Mean CMT at baseline was 215 ± 13 μm and 225 ± 85 μm at the 12-month examination. Two eyes (13.3%) showed CNV extension to the fovea.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab injection can be a beneficial approach for the management of nonsubfoveal CNV secondary to angioid streaks over a 1-year follow-up.
authors.affiliation: Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Battaglia Parodi
authors.affiliation: Fondazione G. B. Bietti per l'Oftalmologia, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Rome, Italy. Electronic address: pierluigi.iacono@libero.it.
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Iacono
authors.affiliation: Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: La Spina
authors.affiliation: Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Berchicci
authors.affiliation: Department of Ophthalmology, Humanitas Clinical and Research Center, Rozzano, Italy; Department of Ophthalmology, Humanitas Gavazzeni, Bergamo, Italy.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Scotti
authors.affiliation: Department of Ophthalmology, Humanitas Gavazzeni, Bergamo, Italy; Department of Ophthalmology, University Hospitals, Leuven, Belgium.
authors.forename: Anita
authors.initials: A
authors.lastname: Leys
authors.affiliation: Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy.
authors.forename: Ugo
authors.initials: U
authors.lastname: Introini
authors.affiliation: Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Bandello
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000793:Angioid Streaks / Q000150:complications / Q000188:drug therapy*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005584:Fovea Centralis; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab